Skip to content
Study details
Enrolling now

Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer

Ohio State University Comprehensive Cancer Center
NCT IDNCT06330805ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

70

Study length

about 3.4 years

Ages

18+

Sex

Male only

Locations

1 site in OH

What this study is about

This trial is testing whether relugolix or leuprolide affects the heart and physical performance in men with prostate cancer. The goal is to see if relugolix might be better for heart health compared to leuprolide, a common treatment for prostate cancer.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Contrast Agent
  • 2.Physical Performance Testing
  • 3.Take Leuprolide
  • +3 more

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Oral

How treatment is administered

Treatment Assignment
Randomized (Open Label)

You are randomly assigned, but you will know your treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

leuprorelin (GnRH agonist; suppresses testosterone (and estrogen) production after initial surge), relugolix

Drug routes

oral (Oral Tablet)

Endpoints

Secondary: Quality of life using EORTC QLQ-C30, Quality of life using EPIC-26, Quality of life using European (Euro) Qol-5-Dimension 5-level (EQ-5D-5L), Quality of life using PROMIS

Procedures

diagnostic, imaging

Body systems

Oncology